Novo Nordisk A/S

NYSE:NVO

Drug Manufacturers - General

Healthcare
$39.43 -1.09%

-$0.48 today

Market cap
$173.82B
Beta
0.35
P/E (TTM)
10.2
EPS (TTM)
$27.45
Dividend yield
4.18%
52W Low $35.12High $74.38

Volume 16.12M

Average 16.05M

NVO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Novo Nordisk A/SNYSE: NVO

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation outflow grows to DKK 0

Q2 FY2026 stock-based compensation was DKK 0, compared with DKK 0 a year earlier. Trailing-twelve-month stock-based compensation was DKK 0.

Context

  • Stock-based compensation amounted to 0.0% of revenue in FY2025, down 0.8 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near DKK 0 or moves back toward the trailing-twelve-month quarterly average of DKK 0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
DKK 0— QoQ
Last fiscal yearDec 2025
DKK 0-100.0% YoY
LTMJun 2026
DKK 0— YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

DKK · from the cash flow

Latest · FY2025
0 DKK
Year-over-year change
-100.0%

Stock-Based Compensation vs competitors

How NVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Stock-based compensation amounts to 0.0% of revenue for NVO, versus a peer median of 1.3%.
NVO Competitors
Stock-Based Compensation for NVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$1.42B USD+11.0%+6.0%1.4%
ABBVAbbVie Inc.LTM Jun 2026$976M USD+4.5%+12.5%1.5%
PFEPfizer Inc.LTM Jun 2026$947M USD+14.9%-2.9%1.5%
MRKMerck & Co., Inc.LTM Jun 2026$892M USD+12.5%—1.3%
LLYEli Lilly and CompanyLTM Jun 2026$649.2M USD+5.8%+19.0%0.8%
AMGNAmgen Inc.LTM Jun 2026$492M USD-3.9%+7.2%1.3%
SNYSanofiLTM Jun 2026€184M EUR+7.6%—0.4%
NVONovo Nordisk A/SLTM Jun 2026DKK 0 DKK——0.0%
AZNAstraZeneca PLCLTM Sep 2026$0 USD——0.0%
GSKGSK plcLTM Jun 2026£0 GBP——0.0%
Peer median (excluding NVO) —+7.6%+7.2%1.3%

Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

DKK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income47.76B55.53B83.68B100.99B102.43B
Depreciation & Amortization6.03B7.36B9.41B19.11B21.98B
Deferred Income Tax11.32B13.54B20.99B26.2B28.11B
Stock-Based Compensation1.04B1.54B2.15B2.29B0
Change in Working Capital(8.66B)(5.54B)(12.25B)2.59B3.74B
Accounts Receivables(12.91B)(10.82B)(14.21B)(14.31B)0
Inventory(1.09B)(4.77B)(7.42B)(9.04B)0
Accounts Payables3.15B6.72B10.02B3.24B0
Other Working Capital2.19B3.34B(631M)22.7B3.74B
Other Non-Cash Items(2.49B)6.46B4.92B(30.21B)(37.16B)
Operating Cash Flow55B78.89B108.91B120.97B119.1B
Capital Expenditures(7.39B)(14.75B)(38.9B)(51.31B)(90.11B)
Acquisitions (Net)(18.28B)(7.08B)0(82.16B)1B
Purchases of Investments(7.11B)(9.74B)(13.29B)(19.81B)(723M)
Sales of Investments1.17B6.65B8.29B24.39B10.67B
Other Investing Activities4M(2.61B)(13.09B)(4.15B)(29.97B)
Investing Cash Flow(31.61B)(24.92B)(43.89B)(128.9B)(79.16B)
Debt Repayment15.47B(2.41B)(1.47B)73.06B24.74B
Common Stock Issued00000
Common Stock Repurchased(19.45B)(24.09B)(29.92B)(20.18B)(1.39B)
Dividends Paid(21.52B)(25.3B)(31.77B)(44.14B)(51.76B)
Other Financing Activities00000
Financing Cash Flow(25.49B)(51.8B)(63.16B)8.74B(28.41B)
Effect of Forex Changes591M(238M)(119M)455M(727M)
Net Change in Cash(1.51B)1.93B1.74B1.26B10.81B
Free Cash Flow47.62B64.13B70.01B69.66B28.99B

Novo Nordisk A/S

NYSE:NVO

Intrinsic Alpha fair value

Locked

Current Price

$39.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.